The Chief Executive Officer and Chief Technologies Officer at United Cannabis, or UCANN, have been working with medical cannabis since it became permissible in California in 1999. They then turned their focus to Colorado when the state began to legalize medical cannabis in 2009.
Together they have more than 30 years’ experience, and United Cannabis has accumulated a huge amount of knowledge about the entire cannabis industry, including engineered facilities, security, regulatory compliance, genetics, cultivation, good manufacturing practices (GMP), proprietary extraction methods, branding, retail operations (SOP), marketing and wholesale distribution.
Upon the legalization of medical cannabis in Colorado, United Cannabis began to work closely with patients who were using cannabis to help with a variety of chronic conditions and illnesses in order to improve their results. They received extremely positive feedback from their patients and this helped the company to grow. At the same time, this provided them with more data and evidence for the effectiveness of particular therapies. It is these cannabinoid sequencing protocols that serve as the basis for United Cannabis’ Prana Bio Nutrient Medicinals and A.C.T. Now Programs.
The company say that they are “accredited with observational data from more than 15,000 patients to date” and their success with the Prana Bio Nutrients and A.C.T. Now Program has drawn a great deal of interest from the medical community.
The Prana Therapeutics program is developing targeted therapies for the prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. They have a Polymolecular Botanical Drug development platform that simultaneously targets multiple mechanisms and de-risks clinical drug development through early stage trials.
The A.C.T. Now program (Advanced Cannabinoid Therapy) helps patients target, personalize and manage ailments through a range of cannabinoid based products. Prana Medicinals is a 100% plant-based hypoallergenic medicine that targets the endocannabinoid system with an integrated approach to personalized patient care. The company’s products provide the widest range of accurately dosed phytocannabinoids and cannabinoids with multiple delivery methods. Patients on the A.C.T. Now program are assigned an individual nurse who puts together a bespoke program. The patients with then continue to work with their assigned nurse to help and fine tune the program.
